Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
81,000
Employees81,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
81,000
Employees81,000

PFE Key Statistics

Market cap
144.31B
Market cap144.31B
Price-Earnings ratio
15.09
Price-Earnings ratio15.09
Dividend yield
6.64%
Dividend yield6.64%
Average volume
49.61M
Average volume49.61M
High today
$26.31
High today$26.31
Low today
$25.75
Low today$25.75
Open price
$25.90
Open price$25.90
Volume
49.88M
Volume49.88M
52 Week high
$27.69
52 Week high$27.69
52 Week low
$20.92
52 Week low$20.92

Stock Snapshot

With a market cap of 144.31B, Pfizer(PFE) trades at $26.20. The stock has a price-to-earnings ratio of 15.09 and currently yields dividends of 6.6%.

On 2026-01-22, Pfizer(PFE) stock moved within a range of $25.75 to $26.31. With shares now at $26.20, the stock is trading +1.7% above its intraday low and -0.4% below the session's peak.

Trading volume for Pfizer(PFE) stock has reached 49.88M, versus its average volume of 49.61M.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.

PFE News

Simply Wall St 2h
Pfizer Valuation Check As Shares Recover Modestly From Longer Term Weakness

Advertisement Recent performance snapshot for Pfizer (PFE) Pfizer (PFE) has moved quietly higher in recent months, with a 1-month return of 4.9% and a past 3-...

Pfizer Valuation Check As Shares Recover Modestly From Longer Term Weakness
TipRanks 11h
Pfizer Advances PF-07248144 With New Drug–Interaction Study, Signaling Quiet Pipeline Progress

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools f...

The Motley Fool 16h
Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap?

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation. Pfizer (PFE +1.45%) is a high-yielding stock...

Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap?

Analyst ratings

57%

of 28 ratings
Buy
39.3%
Hold
57.1%
Sell
3.6%

More PFE News

Simply Wall St 1d
The Bull Case For Pfizer Could Change Following Novavax Matrix-M Adjuvant Licensing Deal - Learn Why

In January 2026, Novavax announced a non-exclusive worldwide license and option agreement giving Pfizer access to its Matrix-M vaccine adjuvant technology for u...

The Bull Case For Pfizer Could Change Following Novavax Matrix-M Adjuvant Licensing Deal - Learn Why
Nasdaq 2d
Ex-Dividend Reminder: Albertsons Companies, Signet Jewelers and Pfizer

Looking at the universe of stocks we cover at Dividend Channel, on 1/23/26, Albertsons Companies Inc (Symbol: ACI), Signet Jewelers Ltd (Symbol: SIG), and Pfize...

Ex-Dividend Reminder: Albertsons Companies, Signet Jewelers and Pfizer
Simply Wall St 2d
Pfizer Novavax Matrix M Deal Adds New Angle To Vaccine Story

Pfizer (NYSE:PFE) has entered a non exclusive global licensing deal with Novavax for access to its Matrix M vaccine adjuvant technology. The agreement allows P...

Pfizer Novavax Matrix M Deal Adds New Angle To Vaccine Story
Benzinga 3d
Novavax Shares Rise After Licensing Deal With Pfizer

Novavax, Inc. (NASDAQ:NVAX) shares are trading higher Tuesday after the company announced it entered into a license agreement with Pfizer, Inc. (NYSE:PFE) for u...

Novavax Shares Rise After Licensing Deal With Pfizer
TipRanks 3d
GSK, Shionogi reach agreement with Pfizer for interest in ViiV Healthcare

GSK (GSK) and Shionogi & Co announced that they have reached agreement together with Pfizer (PFE) for the 11.7% economic interest in ViiV Healthcare Limited cur...

TipRanks 3d
Novavax enters license agreement with Pfizer for use of Matrix-M

Novavax (NVAX) has entered into a license agreement with Pfizer (PFE) for use of Novavax’s Matrix-M adjuvant. Under the terms of the agreement, Pfizer will obta...

The Motley Fool 3d
Down 55%, Should You Buy the Dip on Pfizer?

Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard? Pfizer (PFE 0.93%) is in the Wall Street doghouse. I...

Down 55%, Should You Buy the Dip on Pfizer?

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.